comparemela.com

Latest Breaking News On - Cadila healthcare ltd zydus - Page 1 : comparemela.com

Multiples Alternate Asset Mgt-led group to buy Cadila s animal health biz

Cadila Healthcare Ltd (Zydus Cadila) s wholly-owned material subsidiary Zydus Animal Health and Investments Limited (ZAHL) is set to sell its animal healthcare business to a consortium led by Multiples Alternate Asset Management for nearly Rs 3,000 crore. Zydus Cadila on Wednesday announced that ZAHL has entered into a business transfer agreement (BTA) and other ancillary agreements to sell and transfer Zydus AH, its animal healthcare established markets undertaking to the Multiples-led consortium. The deal is to sell one of the two business undertakings of ZAHL on a slump sale basis as a going concern, for a lump sum consideration of Rs 2,921 crore on a cash-free and debt-free basis, subject to certain closing date adjustments and other conditions. The transaction involves transfer of immovable assets, movable assets, inventory, brands and intangible assets, contracts, licenses and permissions, business records, employees along with employee benefit funds, insurance policies, ot

Zydus seeks DCGI nod for add l indication of Hep C drug in Covid-19 therapy

With the phase-3 clinical trials of its Pegylated Interferon Alpha 2b therapy, PegiHep, showing promising results, Cadila Healthcare Ltd (Zydus Cadila) has applied for an approval for additional indication with the Drugs Controller General of India (DCGI) for the use of PegIFN in the treatment of Covid-19. In what could be a breakthrough in the disease management of Covid-19, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease. According to Zydus Cadila, PegIFN in Covid-19 has several add-on advantages compared to other anti-viral agents with the treatment regimen being less cumbersome and more affordable for patients as Pegylated Interferon Alpha 2b, is a single dose regimen.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.